CARA THERAPEUTICS INC

Cara Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference

05 Apr 2022 06:00:01 By Nasdaq GlobeNewswire

Cara Therapeutics Announces Biomarker Data from KALM-1 and KALM-2 Trials of KORSUVA™ (difelikefalin) Injection Selected for Presentation at National Kidney Foundation Spring Clinical Meetings 2022

04 Apr 2022 15:01:00 By Nasdaq GlobeNewswire

Cara Therapeutics Announces Oral KORSUVA™ (difelikefalin) Improves Itch and Inflammatory Biomarkers in Atopic Dermatitis Patients with Moderate-To-Severe Pruritus

28 Mar 2022 06:00:00 By Nasdaq GlobeNewswire

Cara Therapeutics Announces Oral KORSUVA™ (difelikefalin) Data Selected for Late-Breaking Presentation at 2022 American Academy of Dermatology Annual Meeting

08 Mar 2022 15:01:00 By Nasdaq GlobeNewswire

Cara Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

01 Mar 2022 15:01:00 By Nasdaq GlobeNewswire

Kapruvia® receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodialysis patients

25 Feb 2022 06:15:00 By Nasdaq GlobeNewswire

Cara Therapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022

22 Feb 2022 15:01:00 By Nasdaq GlobeNewswire

Cara Therapeutics to Host Virtual R&D Day on March 11, 2022

18 Feb 2022 06:00:00 By Nasdaq GlobeNewswire

Cara Therapeutics Announces Difelikefalin (KORSUVA™) Injection Achieves Positive Topline Results in Phase 3 Clinical Study in Japan for the Treatment of Pruritus in Hemodialysis Patients

10 Jan 2022 07:00:02 By Nasdaq GlobeNewswire

Cara Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

03 Jan 2022 15:01:00 By Nasdaq GlobeNewswire

Cara Therapeutics Announces CMS Grants TDAPA to KORSUVA™ (difelikefalin) Injection

20 Dec 2021 06:00:00 By Nasdaq GlobeNewswire

Cara Therapeutics to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference

18 Nov 2021 07:30:00 By Nasdaq GlobeNewswire

Cara Therapeutics to Present at Upcoming Investor Conferences

09 Nov 2021 15:30:00 By Nasdaq GlobeNewswire

Cara Therapeutics Reports Third Quarter 2021 Financial Results

08 Nov 2021 15:01:03 By Nasdaq GlobeNewswire

Cara Therapeutics Announces CEO Transition

03 Nov 2021 07:00:03 By Nasdaq GlobeNewswire

Cara Therapeutics to Announce Third Quarter 2021 Financial Results on November 8, 2021

01 Nov 2021 15:15:00 By Nasdaq GlobeNewswire

Cara Therapeutics Presents Late-Breaking Results of KARE Phase 2 Trial of Oral Difelikefalin (Oral KORSUVA™) in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus at the 2021 European Academy of Dermatology and Venereology (EADV) Virtual Congress

04 Oct 2021 06:00:00 By Nasdaq GlobeNewswire

Cara Therapeutics Announces Late-Breaking Presentation at 2021 European Academy of Dermatology and Venereology (EADV) Virtual Congress

29 Sep 2021 06:00:00 By Nasdaq GlobeNewswire

Cara Therapeutics to Present at the the 2021 Cantor Virtual Global Healthcare Conference

24 Sep 2021 06:00:00 By Nasdaq GlobeNewswire

Cara Therapeutics and Vifor Pharma announce U.S. FDA approval of KORSUVA™ (difelikefalin) injection for the treatment of moderate-to-severe pruritus in hemodialysis patients

23 Aug 2021 14:41:29 By Nasdaq GlobeNewswire